These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 3300966)

  • 1. Response to tamoxifen and fluoxymesterone in a group of breast cancer patients with disease recurrence after cessation of adjuvant tamoxifen.
    Fornander T; Rutqvist LE; Glas U
    Cancer Treat Rep; 1987; 71(7-8):685-8. PubMed ID: 3300966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group.
    Morales L; Canney P; Dyczka J; Rutgers E; Coleman R; Cufer T; Welnicka-Jaskiewicz M; Nortier J; Bogaerts J; Therasse P; Paridaens R; ;
    Eur J Cancer; 2007 Jan; 43(2):331-40. PubMed ID: 17134892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.
    Dowsett M; Smith IE; Ebbs SR; Dixon JM; Skene A; Griffith C; Boeddinghaus I; Salter J; Detre S; Hills M; Ashley S; Francis S; Walsh G;
    Clin Cancer Res; 2005 Jan; 11(2 Pt 2):951s-8s. PubMed ID: 15701892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52.
    Ingle JN; Suman VJ; Mailliard JA; Kugler JW; Krook JE; Michalak JC; Pisansky TM; Wold LE; Donohue JH; Goetz MP; Perez EA
    Breast Cancer Res Treat; 2006 Jul; 98(2):217-22. PubMed ID: 16538529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
    Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
    Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
    Baum M; Buzdar A; Cuzick J; Forbes J; Houghton J; Howell A; Sahmoud T;
    Cancer; 2003 Nov; 98(9):1802-10. PubMed ID: 14584060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
    Gasparini G; Toi M; Miceli R; Vermeulen PB; Dittadi R; Biganzoli E; Morabito A; Fanelli M; Gatti C; Suzuki H; Tominaga T; Dirix LY; Gion M
    Cancer J Sci Am; 1999; 5(2):101-11. PubMed ID: 10198732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of radiotherapy in the management of operable locally advanced breast carcinoma: results of a randomized trial by the Eastern Cooperative Oncology Group.
    Olson JE; Neuberg D; Pandya KJ; Richter MP; Solin LJ; Gilchrist KW; Tormey DC; Veeder M; Falkson G
    Cancer; 1997 Mar; 79(6):1138-49. PubMed ID: 9070491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Locally advanced non inflammatory breast cancer treated by combined chemotherapy and preoperative irradiation: updated results in a series of 120 patients].
    Lerouge D; Touboul E; Lefranc JP; Genestie C; Moureau-Zabotto L; Blondon J
    Cancer Radiother; 2004 Jun; 8(3):155-67. PubMed ID: 15217583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
    Berns EM; Foekens JA; Vossen R; Look MP; Devilee P; Henzen-Logmans SC; van Staveren IL; van Putten WL; Inganäs M; Meijer-van Gelder ME; Cornelisse C; Claassen CJ; Portengen H; Bakker B; Klijn JG
    Cancer Res; 2000 Apr; 60(8):2155-62. PubMed ID: 10786679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tamoxifen and fluoxymesterone in advanced breast cancer: a controlled clinical trial.
    Westerberg H
    Cancer Treat Rep; 1980 Jan; 64(1):117-21. PubMed ID: 6991101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy.
    Rudas M; Lehnert M; Huynh A; Jakesz R; Singer C; Lax S; Schippinger W; Dietze O; Greil R; Stiglbauer W; Kwasny W; Grill R; Stierer M; Gnant MF; Filipits M;
    Clin Cancer Res; 2008 Mar; 14(6):1767-74. PubMed ID: 18347178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A randomized clinical trial of adjuvant endocrine therapy after breast conserving surgery for early breast cancer. Cooperative Study Group for Breast Conserving Therapy].
    Nakamura Y; Tominaga T; Nomura Y; Koyama H; Miura S; Morimoto T
    Gan To Kagaku Ryoho; 1994 Jun; 21 Suppl 2():217-25. PubMed ID: 8037485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial.
    Fargeot P; Bonneterre J; Roché H; Lortholary A; Campone M; Van Praagh I; Monnier A; Namer M; Schraub S; Barats JC; Guastalla JP; Goudier MJ; Chapelle-Marcillac I
    J Clin Oncol; 2004 Dec; 22(23):4622-30. PubMed ID: 15505276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tamoxifen versus control after adjuvant, risk-adapted chemotherapy in postmenopausal, receptor-negative patients with breast cancer: a randomized trial (GABG-IV D-93)--the German Adjuvant Breast Cancer Group.
    Kaufmann M; Graf E; Jonat W; Eiermann W; Geberth M; Albert US; Gademann G; Conrad B; Stahl K; von Minckwitz G; Schumacher M;
    J Clin Oncol; 2005 Nov; 23(31):7842-8. PubMed ID: 16258087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant treatment for early breast cancer: the Ludwig breast cancer studies.
    Goldhirsch A; Gelber R
    NCI Monogr; 1986; (1):55-70. PubMed ID: 3774016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined chemotherapy and preoperative irradiation for locally advanced noninflammatory breast cancer: updated results in a series of 120 patients.
    Lerouge D; Touboul E; Lefranc JP; Genestie C; Moureau-Zabotto L; Blondon J
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1062-73. PubMed ID: 15234040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
    Hillner BE
    Cancer; 2004 Sep; 101(6):1311-22. PubMed ID: 15368322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The importance of the histologic grade of invasive breast carcinoma and response to chemotherapy.
    Pinder SE; Murray S; Ellis IO; Trihia H; Elston CW; Gelber RD; Goldhirsch A; Lindtner J; Cortés-Funes H; Simoncini E; Byrne MJ; Golouh R; Rudenstam CM; Castiglione-Gertsch M; Gusterson BA
    Cancer; 1998 Oct; 83(8):1529-39. PubMed ID: 9781946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.